samedan logo
 
 
spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

14th Annual Biomarkers Congress

Biomarkers Congress UK 2019

21-22 February 2019
Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.

Biomarkers are a fundamental part of drug development, playing a critical role in drug discovery, preclinical and clinical development, diagnostics and prognostics. Across two days and over 55 presentations, senior experts will provide a comprehensive look at the marketplace to make sure you leave with an increased knowledge of the current trends influencing biomarker research. 

2019 sees the return of our popular discovery, precision medicine and clinical streams designed to provide updates across multiple therapeutic areas, from market-dominating oncology and neuroscience through to more emerging fields such as infectious, cardiovascular and rare diseases. Benefit further from case studies on topical technology innovation in this space: imaging techniques, proteomics and immuno-assays. We are also pleased to announce an additional two streams highlighting important opportunities in the biomarker market: Biomarkers for Early Detection and Prognosis and Digital Biomarkers.

Key Speakers include:

Mark Fidock, Vice President, AstraZeneca 

Frank Kramer, Director Biomarker Strategist, Bayer 

Thomas Hach, Director Healthcare Systems, Novartis 

Devangi Mehta, Director, Development Biomarkers and Bioanalytical Sciences, Biogen 

Kay-Gunnar Stubenrauch, Head of Large Molecule Bioanalytical Sciences 1, Roche 

Joanne Hackett, Chief Commercial Officer, Genomics England

The two day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions from panels and roundtables through to two workshops on clinical biomarker assay validation and data analytics.  It brings together over 350 senior industry experts and key opinion leaders in biomarkers. For more information about the programme and registration, please contact Angela Fernandez Saez at a.fernandez@oxfordglobal.co.uk

Contact Details: 

General Enquiries: +44 (0) 1865 248455

For speaker opportunities contact j.thomson@oxfordglobal.co.uk
For sponsorship opportunities contact sponsorship@oxfordglobal.co.uk
For information on registration contact marketing@oxfordglobal.co.uk
For press & marketing enquiries contact a.saez@oxfordglobal.co.uk

phone +44 1865 248 455
email marketing@oxfordglobal.co.uk
web https://bit.ly/2zInOAb
email Manchester, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Trial Supply Europe 2019

13-14 March 2019, Milan, Italy

Following on from our largest and most engaging meeting to date, Clinical Trial Supply Europe will be returning to Milan for its 20th year in 2019! The 19th annual edition welcomed pharmaceutical companies across Europe who got together to share knowledge and issues regarding clinical trial supplies, both with regards to operational and technological challenges. Over the two days, delegates discussed issues which affected their business in our dedicated operational and technological streams.
More info >>

Banner of DIA_Europe_Events_95 on Samedan Banner of Drug Delivery Partnership 2018_events_97 on Samedan Banner of PHPL West Coast_events_95 on Samedan

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>


News and Press Releases

Change of Company Name: VTU Technology is now VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement